Details of the Drug Combination

General Information of Drug Combination (ID: DCPIVXM)

• Drug Combination Name: Clofarabine + Mitoxantrone
• Indication: Acute Lymphoblastic Leukemia; Status: Phase 1 [1]
• Component Drugs:
  Clofarabine (DMCVJ86): Small molecular drug
  Mitoxantrone (DMM39BF): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Clofarabine

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[2]
Acute myelogenous leukaemia	2A41	Approved	[3]
Langerhans cell histiocytosis	N.A.	Approved	[3]
Leukemia	N.A.	Approved	[3]
Myelodysplastic syndrome	2A37	Approved	[2]
Plasma cell myeloma	2A83.1	Approved	[3]
Classic Hodgkin lymphoma	N.A.	Investigative	[3]

Clofarabine Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial Penicillin binding protein (Bact PBP)	TTJP4SM	NOUNIPROTAC	Binder	[7]
Ribonucleotide reductase (RIR)	TTX09M4	RIR1_HUMAN; RIR2_HUMAN; RIR2B_HUMAN	Inhibitor	[7]

Clofarabine Interacts with 4 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)	DT4YL5R	S28A3_HUMAN	Substrate	[9]
Equilibrative nucleoside transporter 1 (SLC29A1)	DTXD1TQ	S29A1_HUMAN	Substrate	[9]
Equilibrative nucleoside transporter 2 (SLC29A2)	DTW78DQ	S29A2_HUMAN	Substrate	[9]

Clofarabine Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Deoxycytidine kinase (DCK)	DE9FGNK	DCK_HUMAN	Metabolism	[10]

Clofarabine Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Affects Activity	[11]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[12]

Indication(s) of Mitoxantrone

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[4]
Adult acute monocytic leukemia	N.A.	Approved	[4]
Leukemia	N.A.	Approved	[4]
Solid tumour/cancer	2A00-2F9Z	Approved	[5]
Non-hodgkin lymphoma	2B33.5	Phase 1/2	[6]
Metastatic prostate carcinoma	N.A.	Investigative	[4]

Mitoxantrone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Modulator	[16]

Mitoxantrone Interacts with 5 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[17]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[18]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[18]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[19]
ATP-binding cassette sub-family A member 3 (ABCA3)	DT2T6VQ	ABCA3_HUMAN	Substrate	[20]

Mitoxantrone Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Metabolism	[21]

Mitoxantrone Interacts with 230 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Increases Expression	[22]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[22]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Expression	[23]
Voltage-dependent T-type calcium channel subunit alpha-1G (CACNA1G)	OTGKBRE4	CAC1G_HUMAN	Decreases Expression	[13]
Tyrosine-protein kinase JAK2 (JAK2)	OTBIDOOR	JAK2_HUMAN	Decreases Expression	[13]
Sodium channel subunit beta-2 (SCN2B)	OTFAHJ38	SCN2B_HUMAN	Decreases Expression	[13]
LIM domain-binding protein 3 (LDB3)	OTGQL1AM	LDB3_HUMAN	Decreases Expression	[13]
Creatine kinase M-type (CKM)	OTME0KO7	KCRM_HUMAN	Decreases Expression	[13]
Glutathione peroxidase 1 (GPX1)	OTE2O72Q	GPX1_HUMAN	Increases Expression	[13]
Glycogen phosphorylase, muscle form (PYGM)	OTWLVWTV	PYGM_HUMAN	Decreases Expression	[13]
Dystrophin (DMD)	OTD21T5J	DMD_HUMAN	Decreases Expression	[13]
Myosin-7 (MYH7)	OT4Z9T8N	MYH7_HUMAN	Decreases Expression	[13]
Myosin-6 (MYH6)	OT3YNCH1	MYH6_HUMAN	Decreases Expression	[13]
Troponin T, slow skeletal muscle (TNNT1)	OT8PBOAR	TNNT1_HUMAN	Decreases Expression	[13]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Expression	[13]
Sarcoplasmic reticulum histidine-rich calcium-binding protein (HRC)	OTDLEJ4T	SRCH_HUMAN	Decreases Expression	[13]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[13]
Sodium/potassium-transporting ATPase subunit alpha-2 (ATP1A2)	OTCF8OWW	AT1A2_HUMAN	Decreases Expression	[13]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1)	OT8SPJNX	KCNQ1_HUMAN	Decreases Expression	[13]
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX)	OTDAC6Z0	PRKX_HUMAN	Increases Expression	[13]
Myomesin-2 (MYOM2)	OTD2UOXW	MYOM2_HUMAN	Decreases Expression	[13]
Inward rectifier potassium channel 2 (KCNJ2)	OT2OQEZS	KCNJ2_HUMAN	Increases Expression	[13]
Actin, alpha skeletal muscle (ACTA1)	OTOVGLPG	ACTS_HUMAN	Decreases Expression	[13]
Iroquois-class homeodomain protein IRX-4 (IRX4)	OT0TV6WK	IRX4_HUMAN	Decreases Expression	[13]
Ankyrin-2 (ANK2)	OTWB4R1Y	ANK2_HUMAN	Decreases Expression	[13]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[13]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Expression	[13]
Dual specificity protein phosphatase 4 (DUSP4)	OT6WAO12	DUS4_HUMAN	Increases Expression	[13]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Decreases Expression	[13]
Protein phosphatase 1 regulatory subunit 3A (PPP1R3A)	OTJL9VYP	PPR3A_HUMAN	Decreases Expression	[13]
Caveolae-associated protein 4 (CAVIN4)	OTB1DM2C	CAVN4_HUMAN	Decreases Expression	[13]
Nebulin-related-anchoring protein (NRAP)	OTO6H3YF	NRAP_HUMAN	Decreases Expression	[13]
Ryanodine receptor 2 (RYR2)	OT0PF19E	RYR2_HUMAN	Decreases Expression	[13]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[13]
Histone-lysine N-methyltransferase PRDM16 (PRDM16)	OT0BGA27	PRD16_HUMAN	Decreases Expression	[13]
Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2)	OTFJXVQQ	CA2D2_HUMAN	Decreases Expression	[13]
Atrial natriuretic peptide-converting enzyme (CORIN)	OT4SK7DK	CORIN_HUMAN	Decreases Expression	[13]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Increases Expression	[24]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[23]
Glucocorticoid receptor (NR3C1)	OTCI2YDI	GCR_HUMAN	Decreases Activity	[25]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Affects Activity	[11]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[26]
Retinoic acid receptor alpha (RARA)	OT192V9V	RARA_HUMAN	Affects Mutagenesis	[27]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[23]
Retinoic acid receptor beta (RARB)	OT367U3E	RARB_HUMAN	Increases Expression	[28]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[29]
Protein PML (PML)	OT6SM2GD	PML_HUMAN	Affects Mutagenesis	[27]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[30]
Caspase-2 (CASP2)	OTUDYSPP	CASP2_HUMAN	Increases Expression	[31]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[30]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[30]
Caspase-6 (CASP6)	OTXLD3EC	CASP6_HUMAN	Increases Activity	[30]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Decreases Expression	[32]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[14]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Decreases Expression	[33]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Decreases Expression	[33]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[30]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[26]
Autophagy protein 5 (ATG5)	OT4T5SMS	ATG5_HUMAN	Decreases Expression	[33]
Regulator of G-protein signaling 2 (RGS2)	OT0FSRW7	RGS2_HUMAN	Affects Response To Substance	[15]
Mitochondrial pyruvate carrier 2 (MPC2)	OT0GHXGG	MPC2_HUMAN	Affects Response To Substance	[15]
Molybdenum cofactor sulfurase (MOCOS)	OT0TL3Q5	MOCOS_HUMAN	Affects Response To Substance	[15]
Tripartite motif-containing protein 2 (TRIM2)	OT0V1YVC	TRIM2_HUMAN	Affects Response To Substance	[15]
LEM domain-containing protein 2 (LEMD2)	OT0YLT7L	LEMD2_HUMAN	Affects Response To Substance	[34]
Iroquois-class homeodomain protein IRX-1 (IRX1)	OT0ZN9EJ	IRX1_HUMAN	Affects Response To Substance	[34]
Insulin-like growth factor-binding protein 7 (IGFBP7)	OT1D416P	IBP7_HUMAN	Affects Response To Substance	[15]
Methylosome subunit pICln (CLNS1A)	OT1HL9L1	ICLN_HUMAN	Affects Response To Substance	[15]
D-3-phosphoglycerate dehydrogenase (PHGDH)	OT1LMRTG	SERA_HUMAN	Affects Response To Substance	[15]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2)	OT1LQSGX	MTDC_HUMAN	Affects Response To Substance	[15]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D)	OT1RWFV0	PDE4D_HUMAN	Affects Response To Substance	[15]
TBC1 domain family member 8 (TBC1D8)	OT2011SS	TBCD8_HUMAN	Affects Response To Substance	[15]
Protein FAM117A (FAM117A)	OT2FBGGV	F117A_HUMAN	Affects Response To Substance	[15]
Protein transport protein Sec31A (SEC31A)	OT2U42AC	SC31A_HUMAN	Affects Response To Substance	[15]
DNA-binding protein SATB2 (SATB2)	OT2W80XC	SATB2_HUMAN	Affects Response To Substance	[15]
Large neutral amino acids transporter small subunit 1 (SLC7A5)	OT2WPVXD	LAT1_HUMAN	Affects Response To Substance	[15]
Very long chain fatty acid elongase 5 (ELOVL5)	OT375W1Z	ELOV5_HUMAN	Affects Response To Substance	[34]
Nuclear receptor subfamily 4 group A member 2 (NR4A2)	OT3F9IR2	NR4A2_HUMAN	Affects Response To Substance	[15]
Solute carrier organic anion transporter family member 4A1 (SLCO4A1)	OT3J1G7H	SO4A1_HUMAN	Affects Response To Substance	[15]
Fatty acid CoA ligase Acsl3 (ACSL3)	OT3MWER1	ACSL3_HUMAN	Affects Response To Substance	[15]
Leucine-rich repeat transmembrane protein FLRT3 (FLRT3)	OT3XMZU3	FLRT3_HUMAN	Affects Response To Substance	[15]
ELAV-like protein 4 (ELAVL4)	OT3YH6J6	ELAV4_HUMAN	Affects Response To Substance	[34]
Angiomotin-like protein 1 (AMOTL1)	OT40G45S	AMOL1_HUMAN	Affects Response To Substance	[34]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A)	OT4RF9Z4	PDE8A_HUMAN	Affects Response To Substance	[15]
PRELI domain containing protein 3B (PRELID3B)	OT4TRT4K	PLD3B_HUMAN	Affects Response To Substance	[15]
Argininosuccinate synthase (ASS1)	OT4ZMG0Q	ASSY_HUMAN	Affects Response To Substance	[15]
DNA topoisomerase 1 (TOP1)	OT51O0CF	TOP1_HUMAN	Increases ADR	[35]
Centrosomal protein 15 (CEP15)	OT52961J	CEP15_HUMAN	Affects Response To Substance	[15]
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (OXCT1)	OT536PE7	SCOT1_HUMAN	Affects Response To Substance	[15]
Ubiquitin-like protein ISG15 (ISG15)	OT53QQ7N	ISG15_HUMAN	Affects Response To Substance	[15]
cAMP-responsive element-binding protein-like 2 (CREBL2)	OT58JBNU	CRBL2_HUMAN	Affects Response To Substance	[15]
PACRG-like protein (PACRGL)	OT5DEP0X	PACRL_HUMAN	Affects Response To Substance	[34]
Isocitrate dehydrogenase subunit alpha, mitochondrial (IDH3A)	OT5QQB5L	IDH3A_HUMAN	Affects Response To Substance	[15]
G antigen 6 (GAGE6)	OT5WRC1N	GAGE6_HUMAN	Affects Response To Substance	[15]
Melanoma-associated antigen D1 (MAGED1)	OT6EOLFC	MAGD1_HUMAN	Affects Response To Substance	[15]
Laminin subunit beta-1 (LAMB1)	OT6J9LJR	LAMB1_HUMAN	Affects Response To Substance	[15]
Glutathione peroxidase 3 (GPX3)	OT6PK94R	GPX3_HUMAN	Affects Response To Substance	[15]
Band 4.1-like protein 2 (EPB41L2)	OT6UABPM	E41L2_HUMAN	Affects Response To Substance	[34]
Monocarboxylate transporter 7 (SLC16A6)	OT7BIIZX	MOT7_HUMAN	Affects Response To Substance	[15]
Homeobox protein engrailed-2 (EN2)	OT7EZCM2	HME2_HUMAN	Affects Response To Substance	[15]
Exosome complex exonuclease RRP44 (DIS3)	OT7UPHJS	RRP44_HUMAN	Affects Response To Substance	[15]
Protein LBH (LBH)	OT87AT1X	LBH_HUMAN	Affects Response To Substance	[15]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Increases ADR	[35]
Secreted frizzled-related protein 4 (SFRP4)	OT8PQUVB	SFRP4_HUMAN	Affects Response To Substance	[34]
Mesoderm-specific transcript homolog protein (MEST)	OT8Q4U8Y	MEST_HUMAN	Affects Response To Substance	[15]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Affects Response To Substance	[15]
Exostosin-like 2 (EXTL2)	OT8U672K	EXTL2_HUMAN	Affects Response To Substance	[15]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Affects Response To Substance	[15]
Frizzled-2 (FZD2)	OT952ML1	FZD2_HUMAN	Affects Response To Substance	[15]
Transcription factor MafF (MAFF)	OT9B7MX0	MAFF_HUMAN	Affects Response To Substance	[34]
Pyridoxal phosphate homeostasis protein (PLPBP)	OT9DZ8P6	PLPHP_HUMAN	Affects Response To Substance	[15]
Splicing factor 45 (RBM17)	OT9ROJCL	SPF45_HUMAN	Decreases Response To Substance	[36]
Coxsackievirus and adenovirus receptor (CXADR)	OT9ZP02A	CXAR_HUMAN	Affects Response To Substance	[15]
RING finger and CHY zinc finger domain-containing protein 1 (RCHY1)	OTAE7504	ZN363_HUMAN	Affects Response To Substance	[15]
Transgelin (TAGLN)	OTAEZ0KP	TAGL_HUMAN	Affects Response To Substance	[15]
POM121 and ZP3 fusion protein (POMZP3)	OTAH2JOK	POZP3_HUMAN	Affects Response To Substance	[15]
Transmembrane protein 47 (TMEM47)	OTAJ4CPX	TMM47_HUMAN	Affects Response To Substance	[15]
RCC1 and BTB domain-containing protein 1 (RCBTB1)	OTAYELI8	RCBT1_HUMAN	Affects Response To Substance	[15]
Collagen alpha-1(XI) chain (COL11A1)	OTB0DRMS	COBA1_HUMAN	Affects Response To Substance	[15]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Affects Response To Substance	[15]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)	OTB97VIK	IF2B3_HUMAN	Affects Response To Substance	[15]
Cochlin (COCH)	OTBEHD89	COCH_HUMAN	Affects Response To Substance	[15]
Epoxide hydrolase 1 (EPHX1)	OTBKWQER	HYEP_HUMAN	Increases ADR	[35]
Spondin-1 (SPON1)	OTC06MY4	SPON1_HUMAN	Affects Response To Substance	[15]
Interferon regulatory factor 7 (IRF7)	OTC1A2PQ	IRF7_HUMAN	Affects Response To Substance	[15]
Cocaine esterase (CES2)	OTC647SQ	EST2_HUMAN	Affects Response To Substance	[15]
Mothers against decapentaplegic homolog 2 (SMAD2)	OTC6VB4K	SMAD2_HUMAN	Affects Response To Substance	[15]
Cystathionine gamma-lyase (CTH)	OTC90LA0	CGL_HUMAN	Affects Response To Substance	[15]
KRR1 small subunit processome component homolog (KRR1)	OTCMJ3K3	KRR1_HUMAN	Affects Response To Substance	[15]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Affects Response To Substance	[15]
Interferon-stimulated gene 20 kDa protein (ISG20)	OTCWRJJW	ISG20_HUMAN	Affects Response To Substance	[15]
Tropomyosin alpha-1 chain (TPM1)	OTD73X6R	TPM1_HUMAN	Affects Response To Substance	[15]
Spondin-2 (SPON2)	OTE7JLNM	SPON2_HUMAN	Affects Response To Substance	[15]
Interferon-induced transmembrane protein 1 (IFITM1)	OTECO1G8	IFM1_HUMAN	Affects Response To Substance	[15]
Syndecan-2 (SDC2)	OTEEHY1D	SDC2_HUMAN	Affects Response To Substance	[15]
Schwannomin-interacting protein 1 (SCHIP1)	OTF3FR4A	SCHI1_HUMAN	Affects Response To Substance	[15]
NADH dehydrogenase iron-sulfur protein 5 (NDUFS5)	OTF40UYJ	NDUS5_HUMAN	Affects Response To Substance	[15]
G antigen 7 (GAGE7)	OTF8BTR9	GAGE7_HUMAN	Affects Response To Substance	[15]
Dehydrogenase/reductase SDR family member 2, mitochondrial (DHRS2)	OTFHWIY8	DHRS2_HUMAN	Affects Response To Substance	[15]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Decreases Response To Substance	[37]
Laminin subunit alpha-2 (LAMA2)	OTFROQWE	LAMA2_HUMAN	Affects Response To Substance	[34]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Affects Response To Substance	[15]
Double-stranded RNA-specific editase 1 (ADARB1)	OTGKSZEV	RED1_HUMAN	Affects Response To Substance	[15]
Chordin-like protein 1 (CHRDL1)	OTGMWVVA	CRDL1_HUMAN	Affects Response To Substance	[15]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1)	OTGPN3P8	TIA1_HUMAN	Affects Response To Substance	[15]
Voltage-gated potassium channel subunit beta-2 (KCNAB2)	OTH115IE	KCAB2_HUMAN	Affects Response To Substance	[15]
Nidogen-2 (NID2)	OTHC33FF	NID2_HUMAN	Affects Response To Substance	[15]
Endothelial lipase (LIPG)	OTHEE942	LIPG_HUMAN	Affects Response To Substance	[15]
Chemokine-like factor (CKLF)	OTHLPHA0	CKLF_HUMAN	Affects Response To Substance	[15]
E3 ubiquitin-protein ligase MYCBP2 (MYCBP2)	OTHODA1F	MYCB2_HUMAN	Affects Response To Substance	[15]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Affects Response To Substance	[15]
Basal cell adhesion molecule (BCAM)	OTHZOPSD	BCAM_HUMAN	Affects Response To Substance	[15]
Melanoma-associated antigen 6 (MAGEA6)	OTI8S0O2	MAGA6_HUMAN	Affects Response To Substance	[15]
Laminin subunit gamma-1 (LAMC1)	OTIG527N	LAMC1_HUMAN	Affects Response To Substance	[15]
Leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4)	OTIMWEK5	LGR4_HUMAN	Affects Response To Substance	[15]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA)	OTIOLNHE	LICH_HUMAN	Affects Response To Substance	[15]
Runt-related transcription factor 3 (RUNX3)	OTITK1XD	RUNX3_HUMAN	Affects Response To Substance	[15]
Lymphocyte function-associated antigen 3 (CD58)	OTIUGMGS	LFA3_HUMAN	Affects Response To Substance	[15]
Insulin-like growth factor-binding protein 3 (IGFBP3)	OTIX63TX	IBP3_HUMAN	Affects Response To Substance	[15]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Affects Response To Substance	[15]
Protein S100-P (S100P)	OTJCXNJG	S100P_HUMAN	Affects Response To Substance	[15]
Ectoderm-neural cortex protein 1 (ENC1)	OTJEUB6U	ENC1_HUMAN	Affects Response To Substance	[15]
Transcriptional activator Myb (MYB)	OTJH64IV	MYB_HUMAN	Increases ADR	[35]
Trefoil factor 3 (TFF3)	OTJJDRTU	TFF3_HUMAN	Affects Response To Substance	[15]
Antigen peptide transporter 1 (TAP1)	OTJL27PW	TAP1_HUMAN	Affects Response To Substance	[38]
Calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1)	OTKCR5XL	CK2N1_HUMAN	Affects Response To Substance	[15]
Aldehyde dehydrogenase, mitochondrial (ALDH2)	OTKJ9I3N	ALDH2_HUMAN	Affects Response To Substance	[15]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Affects Response To Substance	[15]
CUGBP Elav-like family member 2 (CELF2)	OTLJJ4VT	CELF2_HUMAN	Affects Response To Substance	[15]
Protein CASC3 (CASC3)	OTLK3K4U	CASC3_HUMAN	Affects Response To Substance	[34]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Affects Response To Substance	[15]
Peroxiredoxin-2 (PRDX2)	OTLWCY9T	PRDX2_HUMAN	Affects Response To Substance	[15]
Homeobox protein Hox-A5 (HOXA5)	OTLWGPQD	HXA5_HUMAN	Affects Response To Substance	[15]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Affects Response To Substance	[15]
Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2)	OTMDVWPS	DYRK2_HUMAN	Affects Response To Substance	[15]
Copper-transporting ATPase 1 (ATP7A)	OTMR3GXP	ATP7A_HUMAN	Decreases Response To Substance	[39]
Neurofilament heavy polypeptide (NEFH)	OTMSCW5I	NFH_HUMAN	Affects Response To Substance	[15]
Death-associated protein kinase 1 (DAPK1)	OTNCNUCO	DAPK1_HUMAN	Affects Response To Substance	[15]
Protein phosphatase inhibitor 2 (PPP1R2)	OTNLOUQR	IPP2_HUMAN	Affects Response To Substance	[15]
HMG box transcription factor BBX (BBX)	OTNQ3QUC	BBX_HUMAN	Affects Response To Substance	[15]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5)	OTNY3VMD	PLCE_HUMAN	Affects Response To Substance	[15]
Melanoma-associated antigen D4 (MAGED4B)	OTO37U7W	MAGD4_HUMAN	Affects Response To Substance	[15]
Beta-secretase 2 (BACE2)	OTO5YQVK	BACE2_HUMAN	Affects Response To Substance	[15]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Response To Substance	[40]
Receptor-type tyrosine-protein phosphatase epsilon (PTPRE)	OTOD5NID	PTPRE_HUMAN	Affects Response To Substance	[15]
Probable serine carboxypeptidase CPVL (CPVL)	OTOJL31C	CPVL_HUMAN	Affects Response To Substance	[15]
Caveolae-associated protein 3 (CAVIN3)	OTOLBK79	CAVN3_HUMAN	Affects Response To Substance	[15]
Ecotropic viral integration site 5 protein homolog (EVI5)	OTOPAP55	EVI5_HUMAN	Affects Response To Substance	[15]
Pre-B-cell leukemia transcription factor 1 (PBX1)	OTORABGO	PBX1_HUMAN	Affects Response To Substance	[15]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Decreases Response To Substance	[41]
GTP cyclohydrolase 1 (GCH1)	OTOZ6NSL	GCH1_HUMAN	Affects Response To Substance	[15]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4)	OTPA0QHW	PLCB4_HUMAN	Affects Response To Substance	[15]
G antigen 4 (GAGE4)	OTPB5C0O	GAGE4_HUMAN	Affects Response To Substance	[15]
Interleukin-13 receptor subunit alpha-2 (IL13RA2)	OTPC2G0X	I13R2_HUMAN	Affects Response To Substance	[15]
Tribbles homolog 1 (TRIB1)	OTPEO17G	TRIB1_HUMAN	Affects Response To Substance	[15]
Tumor protein D52 (TPD52)	OTPKSK43	TPD52_HUMAN	Affects Response To Substance	[15]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C)	OTPL0AI1	ABC3C_HUMAN	Affects Response To Substance	[15]
Eukaryotic translation initiation factor 5A-1 (EIF5A)	OTQ8DJX5	IF5A1_HUMAN	Affects Response To Substance	[15]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Affects Response To Substance	[15]
Histone deacetylase 4 (HDAC4)	OTQNGD32	HDAC4_HUMAN	Affects Response To Substance	[15]
Tissue-type plasminogen activator (PLAT)	OTQPDNAB	TPA_HUMAN	Affects Response To Substance	[15]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1)	OTQRET2B	S5A1_HUMAN	Affects Response To Substance	[15]
Sal-like protein 2 (SALL2)	OTQWI68Q	SALL2_HUMAN	Affects Response To Substance	[15]
G antigen 2A (GAGE2A)	OTRAJ80C	GAG2A_HUMAN	Affects Response To Substance	[15]
Actin, gamma-enteric smooth muscle (ACTG2)	OTRDWUO0	ACTH_HUMAN	Affects Response To Substance	[15]
DNA endonuclease RBBP8 (RBBP8)	OTRHJ3GI	CTIP_HUMAN	Affects Response To Substance	[15]
Cysteine/serine-rich nuclear protein 2 (CSRNP2)	OTRZNC1C	CSRN2_HUMAN	Affects Response To Substance	[34]
Heat shock-related 70 kDa protein 2 (HSPA2)	OTSDET7B	HSP72_HUMAN	Affects Response To Substance	[15]
Guanylate cyclase soluble subunit beta-1 (GUCY1B1)	OTSHPHVB	GCYB1_HUMAN	Affects Response To Substance	[15]
Bone marrow stromal antigen 2 (BST2)	OTU4LCJV	BST2_HUMAN	Affects Response To Substance	[15]
Synaptotagmin-like protein 2 (SYTL2)	OTUIOWKL	SYTL2_HUMAN	Affects Response To Substance	[34]
Max-interacting protein 1 (MXI1)	OTUQ9E0D	MXI1_HUMAN	Affects Response To Substance	[15]
Fibronectin type-III domain-containing protein 3A (FNDC3A)	OTUX3S2I	FND3A_HUMAN	Affects Response To Substance	[15]
HLA class II histocompatibility antigen, DR beta 5 chain (HLA-DRB5)	OTUX5TWM	DRB5_HUMAN	Affects Response To Substance	[15]
Prolyl 4-hydroxylase subunit alpha-1 (P4HA1)	OTV04QE5	P4HA1_HUMAN	Affects Response To Substance	[15]
Forkhead box protein F2 (FOXF2)	OTV20NGX	FOXF2_HUMAN	Affects Response To Substance	[15]
Nicotinamide phosphoribosyltransferase (NAMPT)	OTVJR3GL	NAMPT_HUMAN	Affects Response To Substance	[15]
Poly polymerase tankyrase-1 (TNKS)	OTVOUTPX	TNKS1_HUMAN	Affects Response To Substance	[15]
ADP-ribose glycohydrolase MACROD1 (MACROD1)	OTWFEVRW	MACD1_HUMAN	Affects Response To Substance	[15]
Sorbin and SH3 domain-containing protein 1 (SORBS1)	OTWH8762	SRBS1_HUMAN	Affects Response To Substance	[15]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1)	OTX8L3M5	SAHH2_HUMAN	Affects Response To Substance	[15]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Affects Response To Substance	[42]
Ras-related GTP-binding protein D (RRAGD)	OTXLVWAH	RRAGD_HUMAN	Affects Response To Substance	[34]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B)	OTY94WRA	HM20B_HUMAN	Affects Response To Substance	[15]
Bone morphogenetic protein 7 (BMP7)	OTYATP2K	BMP7_HUMAN	Affects Response To Substance	[15]
Glutamine synthetase (GLUL)	OTYGTCGF	GLNA_HUMAN	Affects Response To Substance	[15]
Complement decay-accelerating factor (CD55)	OTZ3HWTO	DAF_HUMAN	Affects Response To Substance	[15]
BTB/POZ domain-containing protein 3 (BTBD3)	OTZ607YT	BTBD3_HUMAN	Affects Response To Substance	[15]
Zinc finger protein PLAGL1 (PLAGL1)	OTZAO900	PLAL1_HUMAN	Affects Response To Substance	[15]
Ras GTPase-activating protein 1 (RASA1)	OTZJ3LP4	RASA1_HUMAN	Affects Response To Substance	[34]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1)	OTZRWTGA	IQGA1_HUMAN	Affects Response To Substance	[15]

References

• [1] ClinicalTrials.gov (NCT01842672) Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6802).
• [3] Clofarabine FDA Label
• [4] Mitoxantrone FDA Label
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
• [8] Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
• [9] Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
• [10] FDA label of Belinostat. The 2020 official website of the U.S. Food and Drug Administration.
• [11] Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
• [12] Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells. J Korean Med Sci. 2014 Nov;29(11):1464-72. doi: 10.3346/jkms.2014.29.11.1464. Epub 2014 Nov 4.
• [13] Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
• [14] Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
• [15] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [16] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [17] Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
• [18] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [19] Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
• [20] A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33.
• [21] FDA label of Mitoxantrone. The 2020 official website of the U.S. Food and Drug Administration.
• [22] Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
• [23] High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15;82(10):3133-40.
• [24] [Alteration of expression of survivin in HL-60 cells treated with chemotherapeutic drugs]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):347-50.
• [25] Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4929-34. doi: 10.1073/pnas.0812308106. Epub 2009 Mar 2.
• [26] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [27] Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood. 2010 Jan 14;115(2):326-30. doi: 10.1182/blood-2009-07-235051. Epub 2009 Nov 2.
• [28] The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells. Differentiation. 2007 Nov;75(9):883-90. doi: 10.1111/j.1432-0436.2007.00199.x. Epub 2007 Jul 2.
• [29] Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells. Toxicol In Vitro. 2014 Oct;28(7):1259-73. doi: 10.1016/j.tiv.2014.06.011. Epub 2014 Jun 30.
• [30] Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
• [31] Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res. 2004 Jan;2(1):53-61.
• [32] Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Cell Physiol Biochem. 2012;30(3):596-608. doi: 10.1159/000341441. Epub 2012 Jul 27.
• [33] Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells. Arch Toxicol. 2023 Jan;97(1):201-216. doi: 10.1007/s00204-022-03363-6. Epub 2022 Oct 10.
• [34] Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene. 2005 Nov 17;24(51):7542-51. doi: 10.1038/sj.onc.1208908.
• [35] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [36] Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
• [37] A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther. 2008 Feb;7(2):263-70. doi: 10.1158/1535-7163.MCT-07-0445.
• [38] Gene expressions associated with chemosensitivity in human hepatoma cells. Hepatogastroenterology. 2007 Mar;54(74):489-92.
• [39] Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007 May 15;67(10):4860-8. doi: 10.1158/0008-5472.CAN-06-3096.
• [40] Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai). 2011 Aug;43(8):647-53. doi: 10.1093/abbs/gmr050. Epub 2011 Jun 28.
• [41] Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res. 2007 Jun 15;67(12):5831-9. doi: 10.1158/0008-5472.CAN-06-4533.
• [42] Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005 Jan;12(1):90-100. doi: 10.1038/sj.cgt.7700775.